Exponent sees FY25 revenue growth low-single digits, consensus $514.32M

For the full fiscal year 2025 as compared to fiscal year 2024, Exponent (EXPO) anticipates: Revenues before reimbursements to grow in the low-single digits; and, EBITDA1 to be 26.25% to 27.0% of revenues before reimbursements. “We are energized by our market opportunities as we enter 2025. Industries must continue to transform to meet market demands and stay competitive in the setting of accelerating technological change, and at the same time they must meet ever-increasing societal expectations regarding the safety and health of their customers and communities. Exponent is focused on the growth and development of our unparalleled and interconnected ecosystem of scientific and engineering talent, as we stay ahead of the curve and deliver the breakthrough insights that will drive long-term profitable growth,” concluded Dr. Corrigan.